Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

MLA

Neuen, Brendon L., et al. “Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.” Circulation, vol. 150, no. 22, Nov. 2024, pp. 1781–90. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.124.071689.

APA

Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., & Heerspink, H. J. L. (2024). Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation, 150(22), 1781–1790. https://doi.org/10.1161/CIRCULATIONAHA.124.071689

Chicago

Neuen, Brendon L., Robert A. Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V. Badve, Katherine R. Tuttle, et al. 2024. “Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.” Circulation 150 (22): 1781–90. doi:10.1161/CIRCULATIONAHA.124.071689.